StreetAlpha.app
Home › Stocks › MDGL

Madrigal Pharmaceuticals, Inc. (MDGL)

Healthcare
$379.10
▼ −4.45%
LAST CLOSE · NOV 20

Madrigal Pharmaceuticals develops treatments for MASH, a serious liver disease, and sells its approved medicine Rezdiffra. It last closed at $379.10 on Nov 20, down 4.45% on the day. The next earnings report for MDGL is expected around Thu, Feb 18, 2027. For the quarter ended Sep 2026, MDGL reported EPS of $1.83 on revenue of $431.3M, with revenue up 50.1% from a year ago. Over its last 8 reports the stock moved an average of 8.7% the session after earnings. Over the last 12 months MDGL insiders bought $35.0M of stock on the open market and sold $69.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is MDGL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MDGL.

Key Stats

Last 12 months
Results
Revenue
$1.4B
+92.8% vs a year ago
Net income
−$155.5M
−10.9% margin
EPS (diluted)
−$5.35
Free cash flow
−$168.7M
−11.8% margin
Valuation
Market cap
$8.8B
23.2M shares
P/E
–
No P/E while losing money
Price to sales
6.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$514.6M
At Sep 30
Debt
$341.3M
At Sep 30
Shareholder equity
$626.9M
Shares outstanding
23.2M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $180.1M$180.1MFY2024FY2025: $958.4M$958.4MFY2025

From MDGL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 18
Estimated date · Time not announced
Reported EPS
$1.83
Quarter ended Sep 2026
Year ago EPS
-$4.01
Same quarter last year
Revenue
$431.3M
+50.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $2.00Dec '24Mar 2025: -$2.61Mar '25Jun 2025: -$1.50Jun '25Sep 2025: -$4.01Sep '25Dec 2025: -$2.03Dec '25Mar 2026: -$3.25Mar '26Jun 2026: -$1.99Jun '26Sep 2026: $1.83Sep '26Latest $1.83
Revenue by quarter
Dec 2024: $103.3MDec '24Mar 2025: $137.3MMar '25Jun 2025: $212.8MJun '25Sep 2025: $287.3MSep '25Dec 2025: $321.1MDec '25Mar 2026: $311.3MMar '26Jun 2026: $364.3MJun '26Sep 2026: $431.3MSep '26Latest $431.3M
How MDGL moved after its last 8 reports
Average move the session after a report ±8.7%
Nov 3, 2026Time not announced−8.1%
Jul 30, 2026Time not announced−9.8%
May 6, 2026Time not announced+7.4%
Feb 19, 2026Time not announced−11.1%
Nov 4, 2025Time not announced+7.8%
Aug 5, 2025Time not announced+8.6%
May 1, 2025Time not announced−1.9%
Feb 26, 2025Time not announced+15.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MDGLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MDGL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MDGL

Technical Analysis

MDGL · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 10% below its 20 day and 22% below its 50 day average. It is 30% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $371.52, and the nearest resistance the Pivot at $385.47.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 5.6%/day
Key levels
$615.0052 week high+62.2%
$496.53100 day average+31.0%
$494.08200 day average+30.3%
$462.3350 day average+22.0%
$443.30Swing high (Nov 10)+16.9%
$418.4820 day average+10.4%
$393.05Pivot R1+3.7%
$385.47Pivot+1.7%
$379.10Last close
$371.52Pivot S1−2.0%
$353.5452 week low−6.7%
$353.54Swing low (Nov 4)−6.7%
Indicators
RSI (14)26.18Oversold below 30Oversold
MACD-16.84Below its signal lineBearish
Stochastic29.2Middle of its rangeNeutral
ADX (14)20.9Weak trend
Williams %R-80.2Oversold below −80, overbought above −20Oversold
CCI (20)-155.2Oversold below −100, overbought above 100Oversold
Rate of change−5.1%Change over 10 sessionsBearish
ATR (14)$21.12Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MDGL

What happened before

See how MDGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MDGL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MDGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MDGLHow many large options trades hit MDGL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

MDGL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲240 buying vs 184 selling
  • ▼Held by funds -6.8 pts
  • ▲Funds holding +27
  • ▼Superinvestors: 1 added, 4 cut
  • ▲Put/call 0.67 to 0.36
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding443416+6.5%
In funds' top 1079−22.2%
Held by funds95.3%102.1%−6.8 pts
New / increased79 / 16176 / 144+9.1%
Reduced / sold out131 / 53131 / 43+5.7%
Put/call ratio0.360.67−45.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MDGL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MDGL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$35.0M1 buy · 1 insider
Sold$69.5M27 sales · 8 insiders
89% of the selling was under pre-arranged trading plans.
2025-12 sold $27.8M2026-01 sold $25.7M2026-03 sold $2.6M2026-05 sold $3.4M2026-06 sold $517K2026-07 sold $1.4M2026-08 sold $342K2026-09 sold $6.2M2026-11 bought $35.0M2026-11 sold $431KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 6Baker Bros. Advisors LPDirectorBuy91,806$381.49$35.0M
Nov 6Shannon T KelleyGeneral CounselSale plan1,077$400.00$431K
Sep 11William John SiboldPresident and CEOSale plan11,583$538.65$6.2M
Aug 17Shannon T KelleyGeneral CounselSale664$514.97$342K
Jul 20William John SiboldPresident and CEOSale2,500$547.30$1.4M
Jun 1David SoergelChief Medical OfficerSale plan1,042$495.74$517K
Every insider buy and sale for MDGL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MDGL insider trades →

From SEC Form 4 filings by MDGL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MDGL is in one of them and how their past MDGL trades turned out.

MDGL in the AI portfolios
Loading…

MDGL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MDGL in an article yet. Here's the latest on the wider market.

MDGL in the news

MDGL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 19
Who traded MDGL · since 2023
Latest 1 filing
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KApr 10, 2023May 19, 202339 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company based in West Conshohocken, Pennsylvania. It focuses on treatments for MASH, a serious liver disease that can lead to cirrhosis, liver failure and liver cancer. Its main product, Rezdiffra, is an oral medicine taken once a day for adults with moderate to advanced liver scarring who do not have cirrhosis. The company sells Rezdiffra to patients and healthcare providers in the United States and Germany, and it is developing other candidates for the disease.

Headquarters
West Conshohocken, PA